WHO prequalifies Serum Institute’s quadrivalent HPV vaccine CERVAVAC
Source: The Hindu, 12 October 2026
Summary
- The WHO has prequalified the Serum Institute of India's (SII) quadrivalent HPV vaccine CERVAVAC, effective 25 September 2026. UN agencies can now procure it for countries running HPV immunisation programmes.
- It is the first Indian-made quadrivalent HPV vaccine on the WHO list. Until now, all WHO-prequalified HPV vaccines were made outside India.
- The change does not automatically replace Gardasil-4 in India's own programme. The real gain is access to international procurement channels and a domestic WHO-prequalified option.
Key facts for Prelims
- WHO prequalification is not a marketing authorisation. It makes a vaccine eligible for procurement by UN agencies (UNICEF etc.), and the product is placed on the WHO List of Prequalified Vaccines.
- CERVAVAC: India's first indigenously developed gender-neutral quadrivalent HPV vaccine, by Serum Institute of India (Pune). It targets HPV types 6, 11, 16 and 18.
- It is licensed in India for girls and boys aged 9–26 years. It is the first Indian-made quadrivalent HPV vaccine to be WHO-prequalified, and it was nationally licensed before prequalification.
- HPV 16 and 18 are high-risk types behind most cervical cancers; types 6 and 11 cause most anogenital warts. HPV can also cause anal, vulval and vaginal cancers.
- WHO's priority target group is girls aged 9–14, with a one- or two-dose schedule.
- India's national HPV programme uses Merck's Gardasil-4 (quadrivalent). Gardasil 9 and Cervarix are available in the private market.
- Other Indian WHO-prequalified vaccine makers: Bharat Biotech, Biological E, Zydus Lifesciences, GreenSignal Bio Pharma, Haffkine, Panacea Biotec and others.
- Bharat Biotech's Typbar-TCV was the first typhoid conjugate vaccine to be WHO-prequalified.
- Vaccine selection for a national programme depends on regulatory status, evidence, price, supply capacity, presentations, logistics and programme needs.
- WHO's HPV product-choice document lists bivalent Cecolin, Cervarix and Walrinvax; quadrivalent Gardasil; and nonavalent Gardasil-9.
Data and details
- Prequalification effective 25 September 2026.
- Global cervical cancer burden (2020): about 6,04,000 new cases and 3,42,000 deaths (estimate).
- India's national HPV vaccination programme: launched 28 February 2026. It targets about 1.2 crore 14-year-old girls with a free single dose. More than 80 lakh doses had been administered by September 2026, per the Union Health Ministry.
- By end-2025, HPV vaccination had been introduced in 165 countries, yet global first-dose coverage among girls was only about 33%, against the 90% target (girls fully vaccinated by age 15).
- WHO attributes over 95% of cervical cancers to persistent high-risk HPV infection.
- Serum Institute's WHO-prequalified portfolio: BCG, DTP combinations, hepatitis B, Hib, measles, measles-rubella, MMR, meningococcal, pneumococcal, polio, rabies, rotavirus, rubella and malaria, among others.
- Zydus's ZyVac TCV received WHO prequalification in September 2026.
- Notably absent: CERVAVAC is not automatically swapped into the Indian programme. Before this, it was nationally licensed but not WHO-prequalified, and WHO's prequalified HPV portfolio had no Indian-made product.
Static–dynamic linkage
- WHO prequalification is a quality-assurance gateway, not a regulatory approval. It tells UN procurement agencies that a vaccine meets international quality, safety and efficacy standards and manufacturing standards. National regulators still license products for use within their own countries.
- For India it links three themes: self-reliance in vaccines ("pharmacy of the world"), preventive oncology and cervical-cancer elimination, and equitable global access to vaccines in low- and middle-income countries.
Syllabus mapping: GS3 – S&T: biotechnology, indigenisation and everyday applications; GS2 – Health: government health interventions, India's role in global health; GS2 – International institutions (WHO).
Background primer
WHO Vaccine Prequalification
- What it is:
- A service provided to UNICEF and other UN agencies that procure vaccines. The goal is to ensure that vaccines used in immunisation programmes are safe and effective.
- Founded:
- The WHO prequalification programme started in 1987.
- Members:
- It is run by WHO with national regulatory authorities (NRAs) and national control laboratories. NRAs and national control laboratories are responsible for regulatory oversight, testing and release of prequalified vaccines. The norms and standards are developed and adopted by the WHO Expert Committee on Biological Standardization.
- Mandate:
- A vaccine that has been evaluated on data, sample testing and WHO inspection of manufacturing sites, with a positive outcome, is placed on the WHO List of Prequalified Vaccines. Listed vaccines are acceptable in principle for UN procurement, but inclusion does not imply WHO approval of the vaccine; that is the NRAs' prerogative. Procurement agencies must separately check things such as the registration status of the vaccine.
- Why it matters:
- Although WHO is not a regulatory authority, prequalification is recognised as a trusted benchmark. It has also raised manufacturing standards in low- and middle-income countries. About 50% of manufacturers with prequalified vaccines are based in LMICs.
Human Papillomavirus (HPV) and HPV vaccines
- What it is:
- A very common sexually transmitted infection. Persistent infection with high-risk types causes cervical cancer (WHO estimate: over 95% of cases), and it can also cause other anogenital cancers and genital warts.
- Why it matters:
- Vaccinate girls aged 9–14 before exposure, with one or two doses depending on the vaccine and programme. This gives primary prevention that works alongside screening and treatment.
Serum Institute of India (SII)
Additional context
-
CERVAVAC's development: Developed and manufactured by SII with support from the Department of Biotechnology (DBT) and BIRAC, with contributions from the Gates Foundation and WHO's International Agency for Research on Cancer (IARC).
-
WHO's listing records the Central Drugs Standard Control Organization (CDSCO) as the responsible national regulatory authority, an effective date of 25/09/2026, a 36-month shelf life, and 2–8°C storage.
-
GKToday notes this is the 32nd WHO prequalification received by Serum Institute of India for its products.
-
India's national programme (PIB): The PM launched the nationwide HPV Vaccination Programme on 28 February 2026 at Ajmer, Rajasthan. Gardasil-4 is procured through a transparent mechanism in partnership with Gavi, the Vaccine Alliance. The vaccination is recommended by WHO and by India's National Technical Advisory Group on Immunization (NTAGI).
-
Programme design: It covers girls who have completed 14 years but not yet 15. A 90-day campaign mode is followed by availability on routine immunisation days. Vaccination is voluntary, free of cost and needs parental consent, with pre-registration on the U-WIN platform. Girls previously vaccinated with any HPV vaccine, including Cervavac, are excluded.
-
Gavi link: In February 2023, Gavi and the Government of India set up a three-year partnership, with US$250 million to help introduce the HPV and typhoid conjugate vaccines into routine immunisation.
-
Disease burden in India: Cervical cancer is the second most common cancer among women in India, with over 1.2 lakh new cases and nearly 80,000 deaths annually (WHO GLOBOCAN 2022). HPV 16 and 18 account for more than 80% of cervical cancer cases in India.
-
WHO's elimination strategy: 90% HPV vaccination of girls by age 15, 70% cervical screening coverage, and treatment of 90% of women with precancer or cancer, by 2030.
Mains dimensions
- Global-health access: A vaccine licensed in India can now enter the UN procurement channels that supply national programmes, especially in low- and middle-income countries. This matters because global first-dose coverage is about 33% against a 90% target, a gap that more suppliers can help narrow.
- Self-reliance and "pharmacy of the world": India already has a large presence on the WHO list, led by SII (BCG, polio, measles, malaria, etc.) and others such as Bharat Biotech, Biological E, Zydus and Panacea Biotec. CERVAVAC fills the HPV gap, where earlier prequalified products were all foreign-made. Public R&D support from DBT/BIRAC and international partners shows the value of public-private partnership.
- Domestic programme implications: Indian programme choice (Gardasil-4, single dose, procured through Gavi) is not automatically changed. A domestic prequalified option could add competition, price discipline and supply security in future procurement, subject to price, capacity, presentation and logistics.
- Cancer prevention as a public-health strategy: The vaccine is a cancer-prevention vaccine. The WHO strategy rests on three pillars: vaccination, screening and treatment. Vaccination alone, even at 80+ lakh doses so far, must be matched with screening and treatment.
- Gender-neutral vaccination: CERVAVAC is licensed for both sexes (9–26 years), covering anal cancer and genital warts in men. The national programme targets only girls aged 14, so a policy debate on coverage and cost-effectiveness remains.
- Regulatory credibility: Prequalification relies on the national regulator (CDSCO) being effective. It strengthens India's credentials as a quality vaccine exporter but is not a substitute for national licensing.
Possible Mains question
**GS2/GS3 (Health, S&T), 15 marks:** "WHO prequalification of India's first indigenously developed quadrivalent HPV vaccine has been hailed as a milestone. Discuss its significance for India's cervical-cancer prevention goals and for global vaccine equity, and outline the challenges in achieving HPV vaccination targets."
Related topics
- WHO structure and functions; Gavi, UNICEF supply division; Universal Immunisation Programme, U-WIN, NTAGI
- CDSCO, New Drugs and Clinical Trials Rules; DBT/BIRAC; Atmanirbhar Bharat in biotech
- Cervical-cancer elimination (90-70-90 targets); National Programme for Prevention and Control of NCDs
- Vaccine diplomacy (Vaccine Maitri); Indian vaccine manufacturers
Topics: GS2Sci & Tech
All current affairs of 12 October 2026 → · UPSC Current Affairs